Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | MST1R | Q04912 | 2/20 | 0.54 |
| ▸ | HGF | P14210 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30713842 | 1.00 | MET (0.55) | METKDRMST1RHGFAXL | |
| SCHEMBL4483017 | 1.00 | MET (0.55) | METKDRMST1RHGFAXL | |
| SCHEMBL22959969 | 0.92 | PDGFRA (0.53) | METKDRAXLPDGFRA | |
| SCHEMBL29487156 | 0.92 | PDGFRA (0.53) | METKDRAXLPDGFRA | |
| SCHEMBL25233743 | 0.90 | KDR (0.48) | METKDRMST1RHGFAXL | |
| SCHEMBL30465509 | 0.90 | KDR (0.48) | METKDRMST1RHGFAXL | |
| SCHEMBL29487188 | 0.89 | PDGFRA (0.59) | METKDRAXLPDGFRA | |
| SCHEMBL174159 | 0.89 | PDGFRA (0.59) | METKDRAXLPDGFRA | |
| SCHEMBL28343434 | 0.88 | TRPA1 (0.56) | METKDR | |
| SCHEMBL1895559 | 0.87 | PDGFRA (0.65) | METKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304898-B2 | Quinolyl-containing compound and pharmaceutical composition, and use thereof | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-113924288-B | Quinolinyl-containing compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117362275-A | Tyrosine protein kinase inhibitor and application thereof | 广州百霆医药科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2024000615-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND USE THEREOF | 广州百霆医药科技有限公司 | 2024-01-04 | — | — | WO | disclosed |
| CN-112351971-B | Quinoline or quinazoline compound and application thereof | 上海海和药物研究开发股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3778585-B1 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2022-10-19 | — | — | EP | disclosed |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006117552-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| CN-1553899-A | Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds | ������������ʽ���� | 2004-12-08 | — | — | CN | disclosed |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1411046-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885KDR 4/4885MST1R 248/4885 |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | HDAC11, HDAC1, HDAC6 | MET 579/4885KDR 1621/4885MST1R 2213/4885 |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | NR1H2, NR1H3, NR1H4 | MET 72/4885KDR 1874/4885MST1R 274/4885 |
| US-12304898-B2 | Quinolyl-containing compound and pharmaceutical composition, and use thereof | HDAC11, HDAC1, HDAC6 | MET 579/4885KDR 1621/4885MST1R 2213/4885 |
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | MET 3/4885KDR 231/4885MST1R 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.